The science
Bakuchiol is a meroterpene phenol isolated from the seeds of Psoralea corylifolia, and its claim to the retinol-alternative title rests on gene-expression work showing that it up-regulates a similar set of retinoid-responsive genes in skin cells, including those for collagen and extracellular matrix components, despite having no structural resemblance to retinol and no affinity for retinoic acid receptors. The clinical anchor is Dhaliwal and colleagues' prospective, randomised, double-blind study published in the British Journal of Dermatology in 2019: 44 subjects with facial photoageing applied 0.5 percent bakuchiol cream twice daily or 0.5 percent retinol cream once daily for twelve weeks, and both groups showed significant, statistically indistinguishable reductions in wrinkle surface area and hyperpigmentation by facial imaging and dermatologist grading, while the retinol group reported more scaling and stinging. That is a small, single trial, but it is a properly controlled one, and it is the basis for calling bakuchiol comparable to retinol at that concentration. Two further properties are well documented: bakuchiol is photochemically stable and does not sensitise skin to ultraviolet light, which permits daytime use, and it has antioxidant and anti-inflammatory activity in vitro, including inhibition of lipid peroxidation and of some inflammatory mediators. Dose matters for all of it. The trial used 0.5 percent; commercial serums range from about 0.5 to 2 percent; and this formula gives no figure while listing bakuchiol eighth, after three preservatives that are each typically used well below one percent, in a base whose second and third ingredients are the solubilisers needed to dissolve an oil-soluble active into water. The formulation is competent for what it is, since PEG-40 hydrogenated castor oil and polysorbate 20 are standard solubilisers that keep bakuchiol clear and stable in an aqueous vehicle, and sodium phytate chelates metals that would speed its oxidation. But there is no evidence for bakuchiol at concentrations far below 0.5 percent, and no supporting active in the formula to contribute in the meantime. The science supports bakuchiol as a genuine, gentle, photostable retinol alternative at trial doses, and supports this serum only to the extent that its undisclosed dose approaches them.
References 1 ShowHide
- Prospective, randomized, double-blind assessment of topical bakuchiol and retinol for facial photoageing — British Journal of Dermatology (2019)